Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
40914375 2025 NK cells limit the synergistic anti-tumor effect of PD-1 inhibition and βγ-biased IL-2. International journal of biological macromolecules Likely relevant The study investigates a biased IL-2 variant combined with PD-1 inhibitors in a colon cancer mouse model, analyzing NK cells and CD8+ T cell activation, infiltration, and exhaustion. wild-type IL-2; Non-a-IL-2; PD-1 inhibitors Animal colon cancer wild-type IL-2 0/0/0; Non-a-IL-2 0/0/0; PD-1 inhibitors 0/0/0 Awaiting curator check
40959092 2025 Urokinase-type plasminogen activator deficiency enhances CD8+ T cell infiltration and anti-PD-1 therapy efficacy in prostate cancer. Frontiers in immunology Likely relevant The study tests the uPA inhibitor UK122 and anti-PD-1 therapy in mouse models and cell assays, evaluating CD8+ T cell infiltration, cytotoxicity, and PD-1 expression. UK122; anti-PD-1; anti-CD19 CAR Mixed prostate cancer UK122 0/0/0; anti-PD-1 14/36/0; anti-CD19 CAR 0/0/0 Awaiting curator check
40963914 2025 Tumor-responsive cuproptosis nanoinducer realizing efficient PANoptosis for enhanced cancer immunotherapy. Theranostics Likely relevant The study tests nanoparticles inducing cuproptosis combined with immune checkpoint blockade in animal models and measures immune cell infiltration and immunogenic cell death. Elesclomol-Cu@PDPA nanoparticles; immune checkpoint blockade Animal cancer (unspecified in abstract) Elesclomol-Cu@PDPA nanoparticles 0/0/0; immune checkpoint blockade 0/1/0 Awaiting curator check
40983344 2025 Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC. Journal for immunotherapy of cancer Likely relevant The study experimentally tests anlotinib, anti-PD-1, and chloroquine in animal and in vitro models, and reports their effects on immune cell infiltration (CD8+ T cells, M2 macrophages) and the tumor microenvironment. anlotinib; anti-PD-1; chloroquine Animal non-small cell lung cancer anlotinib 0/0/0; anti-PD-1 14/36/0; chloroquine 3/0/1 Awaiting curator check
41005293 2025 Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity Likely relevant The study investigates genetic/pharmacologic attenuation of ATF4 combined with a PD-1 inhibitor in tumor models and measures CD8+ TIL viability and oxidative stress. programmed cell death protein-1 (PD-1) inhibitor Animal various tumor models programmed cell death protein-1 (PD-1) inhibitor 0/0/0 Awaiting curator check
41005300 2025 Phocaeicola vulgatus induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production. Cell reports. Medicine Likely relevant Investigates the effect of microbial metabolites and anti-PD-1 therapy on CD8+ T cell cytotoxicity and tumor models. anti-PD-1; indoleacetic acid Animal hepatocellular carcinoma anti-PD-1 14/36/0; indoleacetic acid 0/0/0 Awaiting curator check
41075789 2025 Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. Cell reports. Medicine Likely relevant The study tests lipid nanoparticle-encapsulated circILNb delivering IL-15 and anti-PD-L1, measuring CD8+ T cell activation and systemic immune responses. circILNb (co-encoding IL-15 and anti-PD-L1 nanobody) Mixed tumors circILNb (co-encoding IL-15 and anti-PD-L1 nanobody) 0/0/0 Awaiting curator check
41125717 2025 Genistein enhances anti-PD-1 efficacy in melanoma by suppressing regulatory T cell differentiation and activity. Scientific reports Likely relevant The study tests genistein alone or with anti-PD-1 therapy in vitro and in a mouse melanoma model, measuring Treg differentiation, CD8+/Treg ratio, and immune infiltration. genistein; anti-PD-1 Mixed melanoma genistein 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
41161002 2025 Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Likely relevant The study tests the combination of PD-1/PD-L1 blockers and ticagrelor on co-cultures of pancreatic cancer cells and TAMs, measuring effects on TAM phagocytosis and TGF-beta1 release. BMS-1; cemiplimab; ticagrelor Cell line pancreatic ductal adenocarcinoma BMS-1 0/0/0; cemiplimab 0/0/0; ticagrelor 0/0/0 Awaiting curator check
41197618 2025 Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. Cell reports. Medicine Likely relevant The study investigates trilaciclib combined with anti-PD-1 antibodies in NSCLC models and reports neutrophil and CD8+ T cell infiltration and activation. trilaciclib; anti-PD-1 antibodies Animal non-small cell lung cancer trilaciclib 0/0/0; anti-PD-1 antibodies 0/0/0 Awaiting curator check
41205593 2025 Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. Cell reports. Medicine Likely relevant The study tests a therapeutic elastase (N17350) across cancer cell lines, tumor models, and patient samples, and measures immunogenic cell death and CD8+ T cell activation. N17350 Mixed cancer N17350 0/0/0 Awaiting curator check
41246302 2025 Immune suppression in MTAP-deficient cancers via glutamate metabolism and CXCL10 downregulation. Frontiers in immunology Likely relevant Tests the glutaminase inhibitor CB-839 in murine tumor models and evaluates its effect on immune signaling and CXCL10 expression. CB-839 Animal MTAP-deficient cancers CB-839 0/0/0 Awaiting curator check
41271647 2025 Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer. Nature communications Likely relevant The study tests chemo-immunotherapy (cisplatin/pemetrexed/anti-PD-1) and targeted inhibitors in mouse models and patient tumors, measuring CD8 T cell recruitment. cisplatin; pemetrexed; anti-PD-1; MEK inhibitors; MDM2 inhibitors Mixed non-small cell lung cancer cisplatin 18/3/11; pemetrexed 3/3/0; anti-PD-1 14/36/0; MEK inhibitors 9/0/0 Awaiting curator check
41315371 2025 Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer. Nature communications Likely relevant The study tests nab-paclitaxel and pembrolizumab in patients with breast cancer and measures immune cell states and pathways in biopsies. nab-paclitaxel; pembrolizumab Patient breast cancer nab-paclitaxel 0/0/0; pembrolizumab 0/0/16 Awaiting curator check
41328155 2025 Co-Delivery of Chemotherapy and Anti-Angiogenic Lipid via DPPA-LNPs Potentiates Anti-PD-1 Immunotherapy. International journal of nanomedicine Likely relevant The study tests a chemotherapeutic nanoplatform combined with a PD-1 inhibitor in orthotopic mouse models and measures immunogenic cell death and TME immune activation. epirubicin; DPPA(EPI) LNPs; programmed cell death protein 1 (PD-1) inhibitor Animal breast cancer and hepatocellular carcinoma epirubicin 0/0/0; DPPA(EPI) LNPs 0/0/0; programmed cell death protein 1 (PD-1) inhibitor 0/0/0 Awaiting curator check
41406067 2025 Combining Radiation and anti-PD-L1 Enhances the Antitumor Activity in Colorectal Cancer via IFN-γ-Dependent Activation of STAT1. Technology in cancer research & treatment Likely relevant The study tests ionizing radiation combined with anti-PD-L1 and the JAK1 inhibitor Itacitinib in a mouse colorectal cancer model and measures CD8+ T-cell infiltration and IFN-gamma levels. anti-PD-L1; Itacitinib Animal colorectal cancer anti-PD-L1 0/15/0; Itacitinib 0/0/0 Awaiting curator check
41613119 2025 Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. Frontiers in immunology Likely relevant The study tests bispecific and combination antibodies targeting PD-L1, TIGIT, and VEGF in vitro and in tumor models, measuring T-cell proliferation and surface marker modulation. HB0036 bispecific antibody; PD-L1 antibody; TIGIT antibody; VEGF blocker Mixed unspecified tumor models HB0036 bispecific antibody 0/0/0; PD-L1 antibody 0/1/0; TIGIT antibody 0/0/0; VEGF blocker 0/0/0 Awaiting curator check
37749237 2024 Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis. Acta pharmacologica Sinica Likely relevant The study tests rosmarinic acid and ginsenoside Rg1 in a mouse xenograft model of colorectal cancer, assessing PD-1/PD-L1 involvement. rosmarinic acid; ginsenoside Rg1; Celecoxib Animal colon cancer rosmarinic acid 0/0/0; ginsenoside Rg1 0/0/0; Celecoxib 6/4/0 Awaiting curator check
38057662 2024 An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature Likely relevant The study experimentally tests dupilumab combined with checkpoint blockade in NSCLC patients and animal models, measuring circulating monocytes and CD8 T cell infiltration. dupilumab; PD-1/PD-L1 checkpoint blockade Mixed non-small cell lung cancer dupilumab 0/0/0; PD-1/PD-L1 checkpoint blockade 0/0/0 Awaiting curator check
38062129 2024 The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cellular & molecular immunology Likely relevant Tests the BCL-2 inhibitor APG-2575 alone and combined with anti-PD-1 in mouse models, measuring macrophage repolarization, chemokine secretion, and T-cell function. APG-2575; anti-PD-1 therapy Animal unspecified cancer (syngeneic and humanized CD34+ mouse models) APG-2575 0/0/0; anti-PD-1 therapy 0/0/0 Awaiting curator check
38101956 2024 Beyond probiotics: postbiotics sensitize cancer cells to immune checkpoint inhibitors. Trends in cancer Likely relevant The study tests postbiotics (phytosphingosine) and immune checkpoint inhibitors, reporting effects on T cell effector responses and NF-kB/NLRC5 activation. phytosphingosine; immune checkpoint inhibitors Mixed cancer phytosphingosine 0/0/0; immune checkpoint inhibitors 0/0/0 Awaiting curator check
38142035 2024 Targeting acid ceramidase enhances antitumor immune response in colorectal cancer. Journal of advanced research Likely relevant The study tests an ASAH1 inhibitor (LCL-521) and anti-PD-1 antibody in human/mouse CRC cell lines and mouse models, measuring ICD, macrophage activation, and T cell infiltration. LCL-521; anti-PD-1 antibody Mixed colorectal cancer (CRC) LCL-521 0/0/0; anti-PD-1 antibody 0/2/0 Awaiting curator check
38207022 2024 Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape. Science (New York, N.Y.) Likely relevant The study experimentally tests recombinant pSAP treatment on dendritic cells and tumor models, measuring its effect on T cell activation and tumor immunity. recombinant pSAP Mixed melanoma recombinant pSAP 0/0/0 Awaiting curator check
38417530 2024 TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12. Gastroenterology Likely relevant The study tests Vactosertib or AMD3100 in combination with anti-PD-L1 in murine models and evaluates immune cell infiltration via flow cytometry and immunofluorescence. Vactosertib; AMD3100; anti-PD-L1 Animal hepatocellular carcinoma Vactosertib 0/0/0; AMD3100 1/7/0; anti-PD-L1 0/15/0 Awaiting curator check
38418879 2024 Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. Nature Likely relevant Examines patient samples and mouse tumor models treated with anti-TIGIT and anti-PD-L1 antibodies, measuring macrophage activation and T cell state remodeling. tiragolumab; atezolizumab Mixed cancer tiragolumab 0/0/0; atezolizumab 0/0/4 Awaiting curator check
← Previous Page 6 of 15 Next →